Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

• Autor(a) principal: Rosinha, A
• Data de Publicação: 2024
• Outros Autores: Rabaça, C, Calais, F, Pinto, JM, Barreira, JV, Fernandes, R, Ramos, R, Fialho, AC, Palma dos Reis, J
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10400.26/49844
• topic: Neoplasias de Próstata Resistentes à Castração; Prostatic Neoplasms, Castration-Resistant

Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.